Best Grants for Teachers in Virgin Islands

The NCAA Jim McKay Graduate Scholarship honors the legacy of journalist Jim McKay by awarding a one-time $10,000 scholarship to one male and one female student-athlete annually. Eligible candidates must have a minimum GPA of 3.5, demonstrate integrity, and show interest in sports communication. There is no limit to the number of nominations from institutions, highlighting the NCAA's commitment to supporting student-athletes in their academic and professional pursuits.

The National Cancer Institute (NCI) seeks to enhance the validation of biomarkers and assays for cancer detection and treatment through its UH3 funding mechanism. This initiative supports multi-disciplinary collaborations to validate existing assays over three years using clinical trial specimens. Emphasis is placed on harmonizing laboratory tests and validating pharmacodynamic markers. Projects should not focus on early-stage technology development but aim for integration into clinical studies as investigational assays.

The NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33) invites research proposals for early phase clinical trials of natural products, including botanicals and dietary supplements, emphasizing scientific validity for further testing. Applicants may receive up to three years of funding for pharmacokinetics and bioavailability studies, with potential for an additional three years to evaluate clinical outcomes. This initiative aims to optimize natural product delivery through innovative study designs.

The FY26 Bus Safety, Accessibility, and Innovation Notice of Funding Opportunity offers up to $10 million for innovative projects aimed at enhancing bus safety and accessibility. Administered by the Federal Transit Administration, this competitive grant invites applications for the development of concepts that improve safety for operators and vulnerable road users, ensuring that public transportation is safer and more accessible for all passengers.

LSC’s Basic Field Grants aim to enhance access to civil legal services for low-income individuals across the U.S. and territories. These grants support eligible organizations for up to three years through a competitive application process. The funding is allocated to specific service areas, which change annually, and focuses on providing comprehensive legal assistance. The program includes three types of service areas, ensuring diverse populations, including agricultural and Native American communities, receive necessary legal support.

The Climate Smart Communities Initiative (CSCI) Grant supports US-based projects aimed at enhancing community resilience against climate change. With a budget of $1.5-2 million, grants typically range from $75,000 to $115,000. CSCI prioritizes projects that focus on historically disinvested populations facing climate vulnerabilities, emphasizing equity, nature-based solutions, and community capacity building. The initiative encourages collaboration between climate adaptation practitioners and local government entities to address climate impacts effectively.

The FY26 Breast Cancer Research Program (BCRP) Breakthrough Award Level 4 supports innovative research with the potential for significant breakthroughs in breast cancer. Applications must address key BCRP challenges or justify exceptions, focusing on impactful solutions. This program mandates clinical trials and requires participation from breast cancer consumer advocates. The funding supports single or partnered Principal Investigators, ensuring comprehensive submission processes to avoid administrative withdrawal.

The DoW Ovarian Cancer Academy Early-Career Investigator Award supports junior faculty in conducting innovative ovarian cancer research. Established in FY09, this unique virtual academy fosters mentorship, collaboration, and networking among Early-Career Investigators (ECIs) and their mentors. Participants engage in monthly webinars and annual workshops, enhancing their research skills while contributing to impactful studies in ovarian cancer. The program aims to cultivate a new generation of highly productive researchers in this critical field.

The Ovarian Cancer Clinical Trial Academy (OCCTA) supports Early-Career Investigators (ECIs) in clinical trial research aimed at effective ovarian cancer treatments. It provides essential mentoring, networking, and skill development needed for executing clinical trials. The FY26 funding will specifically support translational research and early-phase trials, requiring preliminary data and a commitment of at least 25% effort from the ECI. Mentorship is vital, with a focus on experienced clinical trialists guiding ECIs.

The DoW Ovarian Cancer Clinical Trial Award, funded by the U.S. Army Medical Command, aims to accelerate the implementation of clinical trials that significantly impact ovarian cancer treatment. This award supports diverse trial designs, from early proof-of-concept studies to large-scale efficacy trials, evaluating innovative drugs, biologics, and technologies. By fostering research in this critical area, the program seeks to enhance patient outcomes and advance the understanding of ovarian cancer management.

The FY26 Breast Cancer Research Program (BCRP) Breakthrough Award Level 3 supports transformative research aimed at significant advancements in breast cancer treatment. Applicants must address key challenges outlined by the program, ensuring their proposals demonstrate potential for impactful breakthroughs. This funding mechanism, which permits small-scale clinical trials, emphasizes collaboration by requiring research teams to include two breast cancer consumer advocates and allows for a single Principal Investigator or two partnering PIs.

The Ovarian Cancer Research Program (OCRP) Investigator-Initiated Research Award aims to support impactful research addressing critical needs in ovarian cancer and patient care. It requires a robust research plan with preliminary data and allows for studies across all research phases, excluding clinical trials. A unique Partnering Principal Investigator option encourages collaboration between two PIs to enhance research outcomes beyond individual efforts, promoting innovation in the field of ovarian cancer.

The Kate Stokes Memorial Award, established in memory of CLP Programme Officer Kate Stokes, offers a $5,000 grant annually to an exceptional team of CLP alumni. Focused on supporting young conservationists, the award emphasizes teams demonstrating passion and commitment to conservation efforts. The Conservation Leadership Programme (CLP), initiated in 1985, provides vital support for applied biodiversity projects in less developed countries, helping young leaders gain practical conservation experience.

The DoW Ovarian Cancer Pilot Award fosters innovative research that challenges existing paradigms in ovarian cancer. It aims to propel groundbreaking discoveries and advancements in the field. Notably, the award prioritizes originality over scientific merit alone, ensuring that innovative ideas are at the forefront. The application process includes a blinded pre-application screening to maintain confidentiality and integrity, encouraging fresh perspectives in ovarian cancer research.

The FY26 Breast Cancer Research Program's Transformative Breast Cancer Consortium Award fosters significant collaborations that aim to revolutionize care for individuals affected by breast cancer. This award supports a multidisciplinary consortium of leading scientists, clinicians, and advocates to tackle major challenges in breast cancer research. Proposals must address at least one of the program's overarching challenges and demonstrate a transformative impact that cannot be achieved by individual investigators alone.

The FY26 Hearing Restoration Research Program (HRRP) Focused Research Award (FRA) aims to enhance drug discovery and therapeutic development for hearing restoration following military-related auditory injuries. The award supports preclinical and clinical studies aligned with HRRP focus areas. It features two funding levels, including a Partnering Principal Investigator option, and evaluates proposals based on research rationale, strategy, impact, and personnel. Notably, it excludes funding for clinical trials, tinnitus, and vestibular research.

The FY26 Peer Reviewed Medical Research Program Clinical Trial Award promotes the swift initiation of impactful clinical trials for diseases outlined in specific topic areas. It offers two application categories: Clinical Trial Only and Clinical Trial with Planning Phase, supporting various funding levels based on trial phases and participant counts. The total funding of approximately $94.5M aims to support up to 9 applications, with a maximum award period of 4 years, ensuring significant advancements in medical research.

The FY26 Lung Cancer Research Program's Idea Development Award supports innovative, high-risk research aimed at significant breakthroughs in lung cancer treatment. It encourages new concepts in their early stages, requiring preliminary data to demonstrate feasibility, although not necessarily from lung cancer studies. This program also features a New Investigator category, allowing early-career researchers to compete separately for funding, fostering a diverse range of impactful investigations.

The Lung Cancer Patient-Centered Outcomes and Survivorship Award (PCOSA) aims to enhance health outcomes for lung cancer patients by promoting patient-centered research. This FY26 initiative encourages projects that address key areas of survivorship and requires the involvement of lung cancer survivors or caregivers in research teams. Additionally, it supports both translational and clinical research, including pilot clinical trials, to improve the overall patient experience.

The Lung Cancer Translational Research Award (TRA) for FY26 supports innovative translational research aimed at transforming promising lung cancer ideas into clinical applications. This award emphasizes advanced preclinical studies and pilot clinical trials of novel interventions, addressing critical research areas within the Lung Cancer Research Program. Applicants can choose between two funding levels to advance their impactful studies, thereby contributing to significant advancements in lung cancer treatment.

The FY26 Military Burn Research Program (MBRP) Technology/Therapeutic Development Award (TTDA) aims to translate promising preclinical findings into burn products for clinical use in challenging environments. This award supports the development of both tangible products, like medical devices, and knowledge products that enhance health outcomes. A new Mentorship Option encourages collaboration between experienced researchers and junior scientists, fostering the next generation of leaders in military burn care research.

The FY26 Military Burn Research Program (MBRP) Discovery Award aims to support groundbreaking research in combat-relevant burn care. This award encourages innovative and exploratory studies that provide new insights and foundational data for future clinical research. The focus is on novel approaches that lay the groundwork for scientific advancements and product development in burn care, ensuring robust preliminary data generation for subsequent research initiatives.

The DoW Military Burn, Patient-Centered Research Award aims to enhance the implementation of burn care research into clinical practice for military settings. The FY26 program supports clinical trials and research that directly benefit burn patients in resource-limited environments, fostering collaborations between experienced researchers and junior scholars. This initiative addresses critical gaps in combat burn care, ensuring effective interventions and guidelines are developed and utilized in operational battlespaces.